We are live on
!
Find out more
AAP
Ardsley Advisory Partners Portfolio holdings
AUM
$960M
1-Year Est. Return
207.76%
This Fund
S&P 500
This Quarter
Est. Return
-19.38%
1 Year Est. Return
+207.76%
3 Year Est. Return
+554.53%
5 Year Est. Return
+728.66%
10 Year Est. Return
+4,084.52%
AUM
$398M
AUM Growth
-$344M
(-46%)
Cap. Flow
-$248M
Cap. Flow
% of AUM
-62.23%
Top 10 Holdings %
Top 10 Hldgs %
44.07%
Holding
188
New
36
Increased
27
Reduced
23
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$14.6M |
| 2 |
CELG
Celgene Corp
CELG
|
+$10.8M |
| 3 |
TLND
Talend S.A. American Depositary Shares
TLND
|
+$9.74M |
| 4 |
AQUA
Evoqua Water Technologies Corp. Common Stock
AQUA
|
+$9.08M |
| 5 |
ZEN
ZENDESK INC
ZEN
|
+$8.55M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marathon Petroleum
MPC
|
+$27M |
| 2 |
Knight Transportation
KNX
|
+$17.2M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$15.8M |
| 4 |
Magnolia Oil & Gas
MGY
|
+$14.6M |
| 5 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.17% |
| 2 | Healthcare | 20.63% |
| 3 | Industrials | 11.87% |
| 4 | Utilities | 10.14% |
| 5 | Consumer Staples | 5.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Medtronic
MDT
$111B
| $954K | 0.24% |
10,500
+500
| +5% | +$46.7K |
|
|
ZUO
52
DELISTED
Zuora, Inc.
ZUO
| $816K | 0.21% |
+45,000
| New | +$865K |
|
53
SPS Commerce
SPSC
$2.51B
| $741K | 0.19% |
+18,000
| New | +$785K |
|
54
Rapid7
RPD
$642M
| $717K | 0.18% |
+23,000
| New | +$753K |
|
55
Boston Scientific
BSX
$68.5B
| $707K | 0.18% |
20,000
+7,500
| +60% | +$272K |
|
56
Stryker
SYK
$133B
| $706K | 0.18% |
+4,500
| New | +$753K |
|
|
QTNT
57
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $673K | 0.17% |
2,750
| – | – |
|
58
PUT
Meta Platforms (Facebook)
META
$1.51T
| $655K | 0.16% |
5,000
| – | – |
|
|
COUP
59
DELISTED
Coupa Software Incorporated
COUP
| $629K | 0.16% |
+10,000
| New | +$633K |
|
60
Novartis
NVS
$304B
| $601K | 0.15% |
+7,812
| New | +$608K |
|
61
GDS Holdings
GDS
$6.14B
| $577K | 0.15% |
+25,000
| New | +$652K |
|
62
Becton Dickinson
BDX
$45.8B
| $563K | 0.14% |
+2,563
| New | +$595K |
|
|
VTNR
63
DELISTED
Vertex Energy, Inc
VTNR
| $499K | 0.13% |
492,306
+42,893
| +10% | +$64.3K |
|
64
HCA Healthcare
HCA
$92.8B
| $497K | 0.12% |
+4,000
| New | +$537K |
|
65
Zscaler
ZS
$24.5B
| $471K | 0.12% |
+12,000
| New | +$453K |
|
|
MLNX
66
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $462K | 0.12% |
+5,000
| New | +$425K |
|
67
AtriCure
ATRC
$2.01B
| $459K | 0.12% |
15,000
| – | – |
|
68
Merck
MRK
$326B
| $458K | 0.12% |
6,288
-1,572
| -20% | -$111K |
|
69
Viavi Solutions
VIAV
$8.66B
| $452K | 0.11% |
45,000
-20,000
| -31% | -$216K |
|
|
STKL
70
CALL
DELISTED
SunOpta
STKL
| $443K | 0.11% |
+114,500
| New | +$652K |
|
71
Aldeyra Therapeutics
ALDX
$95.3M
| $432K | 0.11% |
52,100
-2,900
| -5% | -$29.7K |
|
72
Harrow
HROW
$1.47B
| $427K | 0.11% |
75,000
-25,000
| -25% | -$107K |
|
|
NVTR
73
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $410K | 0.1% |
25,095
| – | – |
|
74
Cerus
CERS
$585M
| $406K | 0.1% |
80,000
| – | – |
|
|
ACER
75
DELISTED
Acer Therapeutics Inc
ACER
| $402K | 0.1% |
20,000
| – | – |
|
Similar funds
NA
MK
QIM
JVBC
TFP
UWPG
LOAMU
PHS
Ardsley Advisory Partners's Q4 2018 Portfolio in Review
As of Q4 2018, Ardsley Advisory Partners held 188 positions worth $398M, down 46% from $742M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Ardsley Advisory Partners withdrew a net $248M in Q4 2018, closing 84 positions and reducing 23 holdings. Its most notable exit was Marathon Petroleum, an estimated $27M position sold in full.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 16% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Ardsley Advisory Partners opened a new position in CVS Health worth $12.8M.
- Ardsley Advisory Partners's largest Q4 2018 buy was CVS Health: 195,000 shares worth $12.8M.
- Ardsley Advisory Partners added most to Celgene Corp in Q4 2018, an estimated $10.8M increase.
- Ardsley Advisory Partners's biggest Q4 2018 reduction was Progenics Pharmaceuticals Inc, cutting an estimated $7.73M.
- Ardsley Advisory Partners fully exited Marathon Petroleum in Q4 2018, selling an estimated $27M.
- Ardsley Advisory Partners's ten largest holdings make up 44% of its $398M portfolio in Q4 2018.
- Ardsley Advisory Partners opened 36 new positions and closed 84 in Q4 2018.
- Ardsley Advisory Partners's portfolio value fell 46% quarter-over-quarter to $398M.
Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.